Epilepsy: the next generation drugs (a review)

  • Amit Kumar Dhrivastava Department of Pharmacology Universal College of Medical Sciences, Bhairahawa, Nepal1,7
  • Ankita Shrivastav Awadh University Department of Organic Chemistry, Faizabad, India
  • Manish Shrivastav Weifang Medical University, Department of Medicine, China3
  • Anamika Gupta Era University, Department of Biochemistry, Lucknow
  • Shraddha Prakash MRD life Sciences Pvt. Ltd., Lucknow, India
  • Afreen Fatima MRD life Sciences Pvt. Ltd., Lucknow, India
  • Aditi Srivastav Era University, Department of Biochemistry, Lucknow India

Abstract

Epilepsy is a disease characterized by spontaneous recurrence of unprovoked seizures. Seizures and epilepsy are different disorders, and the terms should not be used interchangeably. It is not accurate to refer to seizures as epilepsy, although “seizure disorder” refers to epilepsy. Seizures are common and are treated in all branches of medicine. Approximately 10% of the population will have one or more seizures during their lifetime. Seizures are symptoms that occur in acute illness, i.e., provoked seizures, or in epilepsy, ie, unprovoked seizures. Antiepileptic drugs (AEDs) are pharmacologic agents used to reduce the frequency of epileptic seizures. “Antiepileptic” drug is a misnomer, because these drugs are effective as symptomatic treatment of seizures, i.e., the symptoms of epilepsy, not as treatment of epilepsy itself. Recent discoveries in molecular biology and genetics have elucidated a genetic basis for some epilepsy syndromes, which will lead to new treatments. This review include new AEDs viz; Ganaxolone, Eslicarbazepine acetate, Fluorofelbamate, Huperzine A, Carisbamate (RWJ-333369), Brivaracetam (ucb 34714), 2-Deoxy-D-glucose, Retigabine, T2000 , T2007, Valrocemide, Tonabersat (SB-220453), YKP3089, Propyl isopropyl acetamide, JZP-4, ICA-105665, NAX-5055, Perampanel and Valpromide. 

Downloads

Download data is not yet available.

Author Biographies

Amit Kumar Dhrivastava, Department of Pharmacology Universal College of Medical Sciences, Bhairahawa, Nepal1,7

Department of Pharmacology Universal College of Medical Sciences, Bhairahawa, Nepal1,7

Ankita Shrivastav, Awadh University Department of Organic Chemistry, Faizabad, India

Awadh University Department of Organic Chemistry, Faizabad, India

Manish Shrivastav, Weifang Medical University, Department of Medicine, China3

Weifang Medical University, Department of Medicine, China3

Anamika Gupta, Era University, Department of Biochemistry, Lucknow

Era University, Department of Biochemistry, Lucknow

Shraddha Prakash, MRD life Sciences Pvt. Ltd., Lucknow, India

MRD life Sciences Pvt. Ltd., Lucknow, India

Afreen Fatima, MRD life Sciences Pvt. Ltd., Lucknow, India

MRD life Sciences Pvt. Ltd., Lucknow, India

Aditi Srivastav, Era University, Department of Biochemistry, Lucknow India

Era University, Department of Biochemistry, Lucknow India

References

1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996; 71:576-86.
2. Haerer AF, Anderson DW, Schoenberg BS. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia. 1986; 27:66-75.
3. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996; 71:578-86.
4. Hauser WA, Annegers JF, Kurland LT. The prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991; 32:429-45.
5. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993; 34:453-68.
6. Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin Proc. 1996; 71:570-575.
7. Nohria V, Giller E, Ganaxolone. Neurotherapeutics. 2004; 4:102-105.
8. Carter R.B, Wood P.L, Wieland S, Hawkinson J.E, Belelli D, Lambert J.J, White H.S, Wolf H.H, Mirsadeghi S, Tahir S.H, Bolger M.B, Lan N.C, Gee K.W, Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3(-hydroxy-3(-methyl-5(-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acidA receptor. J. Pharmacol. Exp. Ther. 1997; 280:1284 1295.
9. Le´skiewicz M, Budziszewska B, Jaworska-Feil L, Kubera M, Basta-Kaim Lason W, Inhibitory effect of some neuroactive steroids on cocaine-induced kindling in mice. Polish J. Pharmacol. 2003; 55:1131-1136.
10. Rogawski, M.A., Reddy, D.S., 2004. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho, J.M., Sankar, R., Cavazos, J. (Eds.), Epilepsy: Scientific Foundations of Clinical Practice. Marcel Dekker, New York, pp. 319—355
11. Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski M.A, Avoli M, Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp. Neurol. 2006; 201:519-524.
12. Benes J, Parada A, Figueiredo A.A, Alves P.C. Freitas A.P, Learmonth D.A, Cunha R.A, Garrett J, Soares-da-Silva P, Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J. Med. Chem. 1999; 42:2582-2587.
13. Ambrosio A.F, Silva A.P, Araujo I, Malva J.O, Soaresda- Silva P, Carvalho A.P, Carvalho C.M, Neurotoxic/ neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur. J. Pharmacol. 2000; 406:191–201.
14. Cunha R.A, Coelho J.E, Costenla A.R, Lopes L.V, Parada A, de Mendonca A, Sebastiao A.M, Ribeiro J.A, Effects of carbamazepine and novel 10,11-dihydro-5H dibenz[b,f]azepine- 5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol. Toxicol. 2002; 90:208–213.
15. Almeida L, Soares-da-Silva P, Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007; 4:88-96.
16. Ward J, Caprio V, A radical mediated approach to the core structure of Huperzine A. Tetrahedron Lett. 2006; 47: 553—556.
17. Bialer M, Johannessen S.I, Kupferberg H.J, Levy R.H, Perucca E, Tomson T, Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61:1-48.
18. Wallis R.A, Panizzon K.L, Niquet J, Masaratis L, Baldwin R, Wasterlain C.G, Neuroprotective effects of the anticonvulsant, fluorofelbamate. Epilepsia. 2000; 41(7):162.
19. White H.S, Schachter S, Lee D, Xiaoshen J, Eisenberg D, Anticonvulsant activity of Huperzine A, an alkaloid extract of Chinese club moss (Huperzia serrata). Epilepsia. 2005; 46(8):220.
20. Zangara, A, The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuro-protective properties of interest in the treatment of Alzheimer’s disease. Pharmacol. Biochem. Behav. 2003; 75:675-686.
21. White H, Srivastava A, Klein B et al, The novel investigational neuromodulator RWJ-333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models (abstract). Epilepsia. 2006; 27.
22. Grabenstatter H.L, Dudek F.E, A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia. 2008; 49:1787-1794.
23. Niespodziany I, Leclere N, Matagne A, Wolff C, Brivaracetam modulates Na+ currents expressed in a neuroblastoma cell line compared with carbamazepine. Epilepsia 2009; 50:107.
24. Kaminski R.M, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H, SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology. 2008; 54:715—720.
25. Matagne A, Margineanu D.G, Kenda B, Michel P, Klitgaard H, Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 2008a; 154:1662-1671.
26. Berwick J, Johnston D, Jones M, Martindale J, Martin C, Kennerly AJ, Redgrave P, Mayhew J.E, Fine detail of neurovascular coupling revealed by spatio-temporal analysis of the hemodynamic response to single whisker stimulation in rat barrel cortex. J. Neurophysiol. 2008; 99:787—798.
27. Rundfeldt C, Netzer R, The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci. Lett. 2000; 282:73-76.
28. Spiegelstein O, Yagen B, Bialer M, Structure pharmacokinetic- pharmacodynamic relationships of the new antiepileptic drug valproyl glycinamide. Epilepsia.1999; 40:545–552.
29. Bialer M, Johannessen S.I, Kupferberg H.J, Levy R.H, Loiseau P, Perucca E, Progress report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (EILATV). Epilepsy Res. 2001; 43:11-58.
30. Bialer M, Johannessen S.I, Kupferberg H.J, Levy R.H, Loiseau P, Perucca E, Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002; 51:31-71.
31. Bialer M, Johannessen S.I, Kupferberg H.J, Levy R.H, Perucca E, Tomson T, Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004; 61:1-48.
32. Parsons A.A, Bingham S, Raval P, Read S, Thompson M, Upton N, Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve induced neurovascular reflexes. Br. J. Pharmacol. 2001; 132: 1549-1557.
33. Bialer M, Johannessen S.I, Kupferberg H.J, Levy R.H, Perucca E, Tomson T, Progress report on new antiepileptic drugs: a summary of the tenth Eilat Conference (EILAT X). Epilepsy Res. 2010, 92:89-124.
34. Bialer M, Clinical pharmacology of valpromide. Clin. Pharmacokinet. 1991; 20:114-122.
35. Bialer M, Johannessen S, Kupferberg H.J, Levy R.H, Perucca E, Tomson T, Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. 2007; 73:1-52.
36. Funk A.P, Ricci R, Anderson B.A, Arana A.B, De Colle C, Wang S, George M.S, Single doses of JZP-4 decrease cortical excitability. A transcranial magnetic stimulation study. In: American Epilepsy Society 2008 Annual Meeting.
37. Binnie C.D, Kasteleijn-Nolst Trenité D.G.A, De Korte R.A, Photosensitivity as a model for acute antiepileptic drug studies. Electroencephalogr. Clin. Neurophysiol. 1986; 63:35-41.
38. White H.S, Scholl E.A, Klein B.D, Flynn S.P, Pruess T.H, Green B.R, Zhang L, Bulaj, G, 2009. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically active galanin analog, in epilepsy models. Neurotherapeutics. 2009; 6:372-380.
39. Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y, 2008. Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist, in rodent models of epileptic seizure. In: Poster P02.113 presented at the 60th Annual Meeting of the American Academy of Neurology.
40. Shaltiel, G, Shirley M, Ora K, Belmaker R.H, Agam G, Effect of valproate derivatives on human brain myo-inositol- 1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol. Report. 2007; 59:402-407.
Statistics
93 Views | 92 Downloads
How to Cite
Dhrivastava, A., Shrivastav, A., Shrivastav, M., Gupta, A., Prakash, S., Fatima, A., & Srivastav, A. (2019). Epilepsy: the next generation drugs (a review). Journal of Drug Delivery and Therapeutics, 9(1), 286-292. https://doi.org/10.22270/jddt.v9i1.2279